Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jeffrey Peller

Rheumatology Rome, GA Medical Doctor

NPI 1497810808 CMS profile 158186

1825 Martha Berry Blvd Nw, Rome, GA 30165

Open in the dashboard

General payments

$3,047

163 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jeffrey Peller of Rome, GA is reported in the CMS Open Payments database as having received $3,047 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $322 13
2023 General $622 24
2022 General $448 24
2021 General $358 19
2020 General $448 22
2019 General $849 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Peller
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Jeffrey Peller were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Jeffrey Peller Rheumatology median Middle half National median
2019 $849 $744 $153–$2,687 $163
2020 $448 $462 $98–$2,027 $114
2021 $358 $531 $101–$2,153 $132
2022 $448 $627 $125–$2,303 $149
2023 $622 $741 $145–$2,524 $160
2024 $322 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $748 47 payments
  2. Amgen Inc. $720 31 payments
  3. Pfizer Inc. $326 21 payments
  4. Janssen Biotech, Inc. $265 11 payments
  5. Novartis Pharmaceuticals Corporation $206 12 payments
  6. Aurinia Pharma U.S., Inc. $139 3 payments
  7. GlaxoSmithKline, LLC. $107 6 payments
  8. Horizon Therapeutics plc $102 7 payments
  9. AstraZeneca Pharmaceuticals LP $70 4 payments
  10. UCB, Inc. $68 4 payments
  11. Other $295 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,777 159 payments
  2. Education $270 4 payments
Products named General payments · program years 2019–2024
  1. HUMIRA $464 31 payments
  2. XELJANZ $326 21 payments
  3. RINVOQ $272 15 payments
  4. Prolia $249 15 payments
  5. EVENITY $215 12 payments
  6. TREMFYA $159 5 payments
  7. COSENTYX $145 9 payments
  8. LUPKYNIS $139 3 payments
  9. Otezla $112 5 payments
  10. SIMPONI ARIA $108 6 payments
  11. Other $1,339 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

4,582

Median for Rheumatology: 1,511

Drug cost

$4,416,868

Median for Rheumatology: $1,139,948

Branded share of claims

37.5%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 169 $1,345,958
Enbrel Sureclick Etanercept Brand 131 $1,008,687
Xeljanz Xr Tofacitinib Citrate Brand 83 $556,787
Enbrel Etanercept Brand 51 $410,192
Humira(Cf) Adalimumab Brand 20 $242,732
Cosentyx Sensoready Pen Secukinumab Brand 18 $136,123
Humira Pen Adalimumab Brand 18 $117,502
Rinvoq Upadacitinib Brand 16 $109,490
Xeljanz Tofacitinib Citrate Brand 17 $96,911
Prolia Denosumab Brand 56 $95,783

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 135 billing codes

Paid by Medicare

$4,302,935

Of which drugs: $4,133,153

Medicare patients

902

Average age 74

Services billed

272,616

698 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Osteoporosis 54%
Ischemic heart disease 30%
Diabetes 29%
Chronic kidney disease 28%
Heart failure 26%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 296 28,560 $575,407
Injection, romosozumab-aqqg, 1 mg J3111 Office 20 22,996 $196,257
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 19 4,310 $107,325
Injection, golimumab, 1 mg, for intravenous use J1602 Office 15 10,325 $94,224
Injection, inclisiran, 1 mg J1306 Office 18 7,385 $70,262
Injection, ertapenem sodium, 500 mg J1335 Office 13 178 $1,604
Injection, zoledronic acid, 1 mg J3489 Office 52 260 $1,094
Injection, ceftriaxone sodium, per 250 mg J0696 Office 14 882 $324
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 1,440 $144

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $105
$105 — —
Enbrel
  • Amgen Inc. $35
$35 182 —
BENLYSTA
  • GlaxoSmithKline, LLC. $25
$25 11 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $21
$21 18 —
EVENITY
  • Amgen Inc. $21
$21 — 22,996

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record